Human Genome Sciences has reported 12-week interim results from a Phase IIb clinical trial of Albuferon (albumin- interferon alpha 2b) in combination with ribavirin in patients with genotype 1 chronic hepatitis C who are naïve to interferon alpha-based treatment regimens. The results demonstrate that Albuferon in combination with ribavirin was safe, well-tolerated and showed robust antiviral activity

The data warrant exploring the Albuferon 900-mcg and 1200-mcg doses at two-week intervals in Phase III clinical studies, noted the company.